Dezocine as preemptive analgesia alleviates ultrapulse CO 2 fractional laser treatment induced pain in patients with acne scars.

Autor: Zhang Q; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Li X; Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Wang Y; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Gao N; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Zhang R; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Wu J; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Wu F; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Song P; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Chen M; Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Wang G; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China., Gao L; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jazyk: angličtina
Zdroj: Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 Oct; Vol. 23 (10), pp. 3241-3247. Date of Electronic Publication: 2024 Jun 24.
DOI: 10.1111/jocd.16410
Abstrakt: Background: Ultrapluse CO 2 fractional laser technology has emerged as an effective treatment for scar management. However, one drawback of this modality is the pain caused during the procedure. This study aims to explore the efficacy and safety of dezocine (DZC) as preemptive analgesia for reduction of pain induced by ultrapulse CO 2 fractional laser treatment for acne scars.
Methods: The study cohort included 78 outpatients with acne scars between February and April 2023. Patients were randomly assigned into three groups with intravenous injection (iv) of DZC prior to laser treatment: (1) control, iv of saline; (2) DZC group 1 (DZC_1), iv of DZC at 0.15 mg/kg; and (3) DZC_2, iv of DZC at 0.20 mg/kg. After 30 min, one session of ultrapulse CO 2 fractional laser treatment on acne scars was performed. Hemodynamics, visual analogue scale (VAS), and anxiety visual analog test (AVAT) were monitored prior to, during, and after the procedure.
Results: Operative success rates for patients in the control, DZC_1, and DZC_2 groups were 34.6%, 84.6%, and 100%, respectively. DZC administered with either dosage significantly reduced the VAS and AVAT scores of patients in treatment groups as compared with the subjects in the control group during the course of ultrapulse CO 2 fractional laser treatment. Patients in DZC_1 and DZC_2 groups did not show any significant difference in hemodynamic parameters, VAS, and AVAT scores. Temporary adverse effects such as nausea and dizziness were observed in some subjects after treatment; the symptoms were quickly dissolved after a rest in supine position.
Conclusions: DZC as preemptive analgesia could effectively reduce pain and anxiety induced by ultrapulse CO 2 fractional laser treatment in patients. This study provided an option of preemptive anesthesia to minimize the pain and discomforts associated with laser treatments in clinical practices.
(© 2024 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje